한글목차

오메가 3 처방약 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 17억 5,000만 달러에서 2026년에는 19억 2,000만 달러에 이르고, CAGR 9.9%로 성장할 전망입니다. 지난 몇 년간의 성장은 고중성지방혈증의 높은 유병률, 심혈관 질환에 대한 인식 증가, 고령 인구 증가, 처방용 오메가3 의약품의 가용성, 임상 연구 및 시험 증가에 기인하는 것으로 보입니다.

오메가 3 처방약 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 28억 1,000만 달러에 이르고, CAGR은 10.0%를 나타낼 전망입니다. 예측 기간 동안의 성장 요인으로는 정밀의료의 발전, 개인 맞춤형 치료에 대한 수요 증가, 디지털 헬스 툴의 통합, 신흥 시장에서의 확장, 오메가3 제제의 혁신 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 개인 맞춤형 오메가3 요법 개발, 오메가3 제제 임상시험 증가, 심혈관 위험 관리 솔루션의 성장, 처방용 오메가3 의약품의 접근성 확대, 건강기능식품과 의약품의 통합 강화 등이 있습니다.

심혈관 질환(CVD) 증가는 오메가3 처방약 시장의 성장을 견인할 것으로 예측됩니다. 지질과 유사한 물질인 혈중 중성지방 증가는 심혈관 질환의 위험 증가와 관련이 있으며, 오메가3 보충제는 이러한 중성지방 수치를 조절하고 감소시키는 데 도움이 됩니다. 예를 들어, 미국 정부기관인 국립보건원(NIH)에 따르면 2025년 8월 기준 2025년부터 2050년까지 심혈관질환 유병률은 90%, 사망률은 73%, 장애조정생존년수(DALYs)는 55% 증가하고 사망자 수는 2,050만 명에서 3,560만 명으로 증가할 것으로 예측했습니다. 증가할 것으로 예측되고 있습니다. 따라서 심혈관 질환의 부담 증가는 오메가3 처방약 수요 증가를 촉진할 것으로 예측됩니다.

오메가3 처방약 시장의 주요 기업들은 체내 중성지방 생성을 억제하는 캡슐제 등의 제품 출시에 주력하고 있습니다. 캡슐제는 의약품 또는 건강보조식품의 제형으로, 일반적으로 특정 유효성분을 젤라틴 또는 이와 유사한 껍질로 덮여 있어 섭취가 용이한 형태로 되어 있습니다. 예를 들어, 2023년 3월 영국에 본사를 둔 제네릭 의약품 및 라이선싱 의약품 전문 다국적 기업인 히쿠마 파마슈티컬스(Hikuma Pharmaceuticals)가 미국에서 '이코사펜틸 캡슐 0.5g'을 출시했습니다. 에이코사펜타엔산(EPA)을 함유한 이 캡슐은 중증 고중성지방혈증을 앓고 있는 성인의 중성지방 수치를 낮추기 위한 목적으로 개발되었습니다. 이번 출시는 의약품 등급의 오메가3 제품에 대한 수요 증가에 대응하고 고중성지방혈증에 대한 효과적인 치료법을 제공하기 위한 것입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Omega-3 prescription drugs reduce triglyceride levels (a fat-like substance) in the blood and increase good cholesterol (HDL) levels. Omega-3 fatty acids are nutrients obtained from food or supplements that support overall health and are essential for building and maintaining every cell wall in the body.

The main types of omega-3 prescription drugs include Vascepa, Lovaza, and others. Vascepa is used in adults to lower the risk of heart attack, stroke, and certain heart conditions that require hospitalization. It is an FDA-approved medication for adults with high triglyceride levels and two or more additional cardiovascular risk factors, such as high blood pressure, high cholesterol, or obesity. Omega-3 prescription drugs are used to treat hypertriglyceridemia and other conditions, and they are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

Tariffs have impacted the omega-3 prescription drugs market by increasing the cost of imported raw materials and active pharmaceutical ingredients (APIs), which has elevated production costs and affected the availability of certain drug formulations. The segments most affected include combination EPA and DHA products like Lovaza and emerging formulations in clinical trials, particularly in regions such as North America and Europe that rely on imports. While the tariffs create cost pressures, they have also encouraged local manufacturing and supply chain diversification, which may strengthen domestic production capabilities and support long-term market resilience.

The omega 3 prescription drugs market research report is one of a series of new reports from The Business Research Company that provides omega 3 prescription drugs market statistics, including omega 3 prescription drugs industry global market size, regional shares, competitors with a omega 3 prescription drugs market share, detailed omega 3 prescription drugs market segments, market trends and opportunities, and any further data you may need to thrive in the omega 3 prescription drugs industry. This omega 3 prescription drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The omega 3 prescription drugs market size has grown strongly in recent years. It will grow from $1.75 billion in 2025 to $1.92 billion in 2026 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to high prevalence of hypertriglyceridemia, rising awareness of cardiovascular diseases, increasing geriatric population, availability of prescription omega-3 drugs, growth in clinical research and trials.

The omega 3 prescription drugs market size is expected to see strong growth in the next few years. It will grow to $2.81 billion in 2030 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to advancements in precision medicine, rising demand for personalized therapies, integration of digital health tools, expansion in emerging markets, innovation in omega-3 drug formulations. Major trends in the forecast period include personalized omega-3 therapy development, increased clinical trials for omega-3 formulations, growth in cardiovascular risk management solutions, expansion of prescription omega-3 drug accessibility, enhanced nutraceutical-pharmaceutical integration.

Rising cases of cardiovascular diseases (CVDs) are expected to drive growth in the omega-3 prescription drug market. Elevated blood triglyceride levels, a fatty-like substance, are associated with an increased risk of cardiovascular disorders, and omega-3 supplements help regulate and reduce these triglyceride levels. For example, in August 2025, according to the National Institutes of Health, a US-based government agency, between 2025 and 2050, cardiovascular prevalence is projected to rise by 90%, mortality by 73%, and disability-adjusted life years (DALYs) by 55%, with deaths increasing from 20.5 million to 35.6 million. Consequently, the growing burden of cardiovascular diseases is expected to propel demand for omega-3 prescription drugs.

Leading companies in the omega-3 prescription drug market are focusing on product launches, such as capsules, which help lower the body's production of triglycerides. Capsules are pharmaceutical or dietary supplement dosage forms, typically consisting of a gelatin or similar shell enclosing a specific amount of active ingredients in a convenient, ingestible format. For instance, in March 2023, Hikma Pharmaceuticals, a UK-based multinational company specializing in generic and in-licensed pharmaceutical products, launched Icosapent Ethyl Capsules, 0.5g, in the US. These capsules, containing eicosapentaenoic acid (EPA), are indicated for reducing triglyceride levels in adults with severe hypertriglyceridemia. This launch addresses the rising demand for pharmaceutical-grade omega-3 products and provides an effective therapy for high triglyceride levels.

In July 2024, KD Pharma, a Europe-based contract development and manufacturing organization (CDMO) specializing in pharmaceutical and nutritional lipids, acquired DSM-Firmenich's MEG-3 fish oil business, including production facilities in Peru and Canada and around 200 employees, for an undisclosed amount. This strategic acquisition allows KD Pharma to strengthen its presence across the food, beverage, dietary supplement, and pharmaceutical sectors. DSM-Firmenich's MEG-3 business is closely connected to omega-3 products.

Major companies operating in the omega 3 prescription drugs market are Pfizer Inc., Sanofi S.A., Amarin Corporation plc, GlaxoSmithKline plc, AstraZeneca plc, Merck & Co. Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, BASF SE, DSM Nutritional Products, AbbVie Inc., Eli Lilly and Company, Bayer AG, Shire Pharmaceuticals, Mylan NV, Teva Pharmaceutical Industries Ltd., Horizon Therapeutics, Kyowa Kirin Co. Ltd., Sumitomo Pharma Co. Ltd.

North America was the largest region in the omega 3 prescription drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the omega 3 prescription drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the omega 3 prescription drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The omega 3 prescription drugs market consists of sales of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Omega 3 Prescription Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses omega 3 prescription drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for omega 3 prescription drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The omega 3 prescription drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Type: Vascepa; Lovaza; Other Type
• 2) By Application Type: Hypertriglyceridemia; Other Application Type
• 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• Subsegments:
• 1) By Vascepa: Pure EPA (Eicosapentaenoic Acid) Formulation; Indications For Cardiovascular Risk Reduction
• 2) By Lovaza: Combination Of EPA And DHA (Docosahexaenoic Acid); Indications For Hypertriglyceridemia Management
• 3) By Other Types: Epanova (Omega-3 Carboxylic Acids); Omega-3 Formulations In Clinical Trials; Other Prescription Omega-3 Products
• Companies Mentioned: Pfizer Inc.; Sanofi S.A.; Amarin Corporation plc; GlaxoSmithKline plc; AstraZeneca plc; Merck & Co. Inc.; Novartis AG; Takeda Pharmaceutical Company Limited; Boehringer Ingelheim GmbH; BASF SE; DSM Nutritional Products; AbbVie Inc.; Eli Lilly and Company; Bayer AG; Shire Pharmaceuticals; Mylan NV; Teva Pharmaceutical Industries Ltd.; Horizon Therapeutics; Kyowa Kirin Co. Ltd.; Sumitomo Pharma Co. Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Omega 3 Prescription Drugs Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Omega 3 Prescription Drugs Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Omega 3 Prescription Drugs Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Omega 3 Prescription Drugs Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Sustainability, Climate Tech & Circular Economy
  • 4.1.4 Artificial Intelligence & Autonomous Intelligence
  • 4.1.5 Industry 4.0 & Intelligent Manufacturing
• 4.2. Major Trends
  • 4.2.1 Personalized Omega-3 Therapy Development
  • 4.2.2 Increased Clinical Trials For Omega-3 Formulations
  • 4.2.3 Growth In Cardiovascular Risk Management Solutions
  • 4.2.4 Expansion Of Prescription Omega-3 Drug Accessibility
  • 4.2.5 Enhanced Nutraceutical-Pharmaceutical Integration

5. Omega 3 Prescription Drugs Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Cardiologists & Clinics
• 5.3 Specialty Pharmacies
• 5.4 Retail Pharmacies
• 5.5 Elderly Patients / Chronic Disease Patients

6. Omega 3 Prescription Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Omega 3 Prescription Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Omega 3 Prescription Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Omega 3 Prescription Drugs Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Omega 3 Prescription Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Omega 3 Prescription Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Omega 3 Prescription Drugs Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Omega 3 Prescription Drugs Market Segmentation

• 9.1. Global Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Vascepa, Lovaza, Other Type
• 9.2. Global Omega 3 Prescription Drugs Market, Segmentation By Application Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hypertriglyceridemia, Other Application Type
• 9.3. Global Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
• 9.4. Global Omega 3 Prescription Drugs Market, Sub-Segmentation Of Vascepa, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Pure EPA (Eicosapentaenoic Acid) Formulation, Indications For Cardiovascular Risk Reduction
• 9.5. Global Omega 3 Prescription Drugs Market, Sub-Segmentation Of Lovaza, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Combination Of EPA And DHA (Docosahexaenoic Acid), Indications For Hypertriglyceridemia Management
• 9.6. Global Omega 3 Prescription Drugs Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Epanova (Omega-3 Carboxylic Acids), Omega-3 Formulations In Clinical Trials, Other Prescription Omega-3 Products

10. Omega 3 Prescription Drugs Market Regional And Country Analysis

• 10.1. Global Omega 3 Prescription Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Omega 3 Prescription Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Omega 3 Prescription Drugs Market

• 11.1. Asia-Pacific Omega 3 Prescription Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Segmentation By Application Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Omega 3 Prescription Drugs Market

• 12.1. China Omega 3 Prescription Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Segmentation By Application Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Omega 3 Prescription Drugs Market

• 13.1. India Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Segmentation By Application Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Omega 3 Prescription Drugs Market

• 14.1. Japan Omega 3 Prescription Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Segmentation By Application Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Omega 3 Prescription Drugs Market

• 15.1. Australia Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Segmentation By Application Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Omega 3 Prescription Drugs Market

• 16.1. Indonesia Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Segmentation By Application Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Omega 3 Prescription Drugs Market

• 17.1. South Korea Omega 3 Prescription Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Segmentation By Application Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Omega 3 Prescription Drugs Market

• 18.1. Taiwan Omega 3 Prescription Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Segmentation By Application Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Omega 3 Prescription Drugs Market

• 19.1. South East Asia Omega 3 Prescription Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Segmentation By Application Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Omega 3 Prescription Drugs Market

• 20.1. Western Europe Omega 3 Prescription Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Segmentation By Application Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Omega 3 Prescription Drugs Market

• 21.1. UK Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Segmentation By Application Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Omega 3 Prescription Drugs Market

• 22.1. Germany Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Segmentation By Application Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Omega 3 Prescription Drugs Market

• 23.1. France Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Segmentation By Application Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Omega 3 Prescription Drugs Market

• 24.1. Italy Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Segmentation By Application Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Omega 3 Prescription Drugs Market

• 25.1. Spain Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Segmentation By Application Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Omega 3 Prescription Drugs Market

• 26.1. Eastern Europe Omega 3 Prescription Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Segmentation By Application Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Omega 3 Prescription Drugs Market

• 27.1. Russia Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Segmentation By Application Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Omega 3 Prescription Drugs Market

• 28.1. North America Omega 3 Prescription Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Segmentation By Application Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Omega 3 Prescription Drugs Market

• 29.1. USA Omega 3 Prescription Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Segmentation By Application Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Omega 3 Prescription Drugs Market

• 30.1. Canada Omega 3 Prescription Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Segmentation By Application Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Omega 3 Prescription Drugs Market

• 31.1. South America Omega 3 Prescription Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Segmentation By Application Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Omega 3 Prescription Drugs Market

• 32.1. Brazil Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Segmentation By Application Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Omega 3 Prescription Drugs Market

• 33.1. Middle East Omega 3 Prescription Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Segmentation By Application Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Omega 3 Prescription Drugs Market

• 34.1. Africa Omega 3 Prescription Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Segmentation By Application Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Omega 3 Prescription Drugs Market Regulatory and Investment Landscape

36. Omega 3 Prescription Drugs Market Competitive Landscape And Company Profiles

• 36.1. Omega 3 Prescription Drugs Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Omega 3 Prescription Drugs Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Omega 3 Prescription Drugs Market Company Profiles
  • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Amarin Corporation plc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

37. Omega 3 Prescription Drugs Market Other Major And Innovative Companies

• Merck & Co. Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, BASF SE, DSM Nutritional Products, AbbVie Inc., Eli Lilly and Company, Bayer AG, Shire Pharmaceuticals, Mylan NV, Teva Pharmaceutical Industries Ltd., Horizon Therapeutics, Kyowa Kirin Co. Ltd., Sumitomo Pharma Co. Ltd.

38. Global Omega 3 Prescription Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Omega 3 Prescription Drugs Market

40. Omega 3 Prescription Drugs Market High Potential Countries, Segments and Strategies

• 40.1 Omega 3 Prescription Drugs Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Omega 3 Prescription Drugs Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Omega 3 Prescription Drugs Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer